| Peer-Reviewed

A 25-year-female with Diffuse Intrinsic Pontine Glioma Surviving for More than Nine Years Following Treatment with Antineoplastons

Received: 17 December 2021     Accepted: 19 January 2022     Published: 5 February 2022
Views:       Downloads:
Abstract

Rationale: Diffuse intrinsic pontine glioma (DIPG) is a lethal brain tumor and leading cause of brain tumor–related death in children. Over the past few decades, clinical trials have shown no improvement in outcome. Most DIPGs occur in the pediatric population. Adult brainstem gliomas are rare, constitute less than 2% of adult gliomas, and show a slight male predominance. The case of this 25-year-old female is presented to detail and discuss the use of Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal) in the treatment of DIPG that persisted despite radiation therapy (RT) and temozolomide. Objectives: The patient described was treated at the Burzynski Clinic (BC), as a special exception, according to the phase II protocol, BT-09, which utilized Antineoplastons A10 and AS2-1 (ANP therapy) in the treatment of brain tumors. The delivery of ANP therapy was via a subclavian catheter and infusion pump. Tumor response to therapy was measured by sequential magnetic resonance imaging (MRI) of the brain. Overall Survival (OS) and Adverse Events (AES) were also documented. Findings: At her presentation to the BC, the patient complained of diplopia, left-sided weakness, and difficulty walking. On physical exam, she was alert and orientated. Her cranial nerves were intact. There was weakness of the left-sided extremities. Deep tendon reflexes were equal bilaterally with down-going toes bilaterally. Reports of the original brain MRIs in Argentina suggested a DIPG with extension to the medulla and cerebellum. In addition, tumor biopsy confirmed a grade 3 astrocytoma. Following radiation therapy (RT) and temozolomide in Argentina, the patient was treated at BC for persistent disease with ANP therapy. Sequential MRI imaging of the residual tumor, which was non-enhancing, showed no change in size during therapy. However, the patient did achieve resolution of her neurologic signs and symptoms and has survived more than nine years since first being seen at BC. Correspondence with the patient on September 9, 2021 indicated she was feeling fine, had a healthy child, and was enjoying life. Conclusions: We have presented here the case of an adult female with a DIPG who had resolution of signs and symptoms and survived more than nine years after ANP therapy. For patients with DIPG (or other high-grade astrocytoma), who do not qualify for/refuse RT or show persistent or progressive disease following RT and/or chemotherapy, ANP therapy is an effective therapeutic option. In collaboration with the FDA confirmatory Phase II and Phase III studies have been developed.

Published in International Journal of Clinical Oncology and Cancer Research (Volume 7, Issue 1)
DOI 10.11648/j.ijcocr.20220701.11
Page(s) 1-7
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Brain Tumor, Diffuse Intrinsic Brainstem Glioma, H3-K27M Diffuse Midline Glioma, Antineoplastons, Phase II and III Studies

References
[1] Epstein F, Farmer JP. (1993) Brain-stem glioma growth patterns. J. Neurosurg, 78, 408–412.
[2] Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, et al. (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet, 44 (3), 251–3.10.1038/ng.1102.
[3] Salmaggi A, Fariselli L, Milanesi I, Lamperti E, Silvani A, Bizzi A, et al. (2008) Natural history and management of brainstem gliomas in adults. A retrospective Italian study. J Neurol, 255 (2), 171–7.10.1007/s00415-008-0589-0.
[4] Burzynski, SR, Janicki, T, Burzynski, GS, Beenken, S. (2021) Long-term survival (27.7 years) following IV Antineoplaston Therapy (ANP) in a 36-year-old-female with a progressive diffuse intrinsic pontine glioma (DIPG). Int J Radiol Imaging Technol, 7, 073-078. doi: 10.23937/2572-3235.1510073.
[5] Theeler BJ, Ellezam B, Melguizo-Gavilanes I, de Groot JF, Mahajan A, Aldape KD, et al. (2015) Adult brainstem gliomas: correlation of clinical and molecular features. J Neurol Sci, 353 (1–2): 92–7.10.1016/j.jns.2015.04.014.
[6] Kesari S, Kim RS, Markos V, et al. (2008) Prognostic factors in adult brainstem gliomas: A multicenter retrospective analysis of 101 vases. J Neurooncol, 88 (2), 175-183. doi: 10.1007/211060-1. 008-9545-1.
[7] Hu J, Western S, Kesari S. Brainstem glioma in adults. (2016) Front Oncol, 6, 180. doi: 10.3389/fonc.2016.00180.
[8] Roujeau T, Machado G, Garnett M, et al. (2007) Stereotactic biopsy of diffuse pontine lesions in children. J Neurosurg, 107, 1–4. Dom Glioma in Sdultsi.org/10.3171/PED-07/07/001.
[9] Cage TA, Samagh SP, Mueller S, Nicolaides T, Haas-Kogan D, Prados M, Banerjee A, Auguste KI, Childs NG. (2013) Feasibility, safety, and indications for surgical biopsy of intrinsic brainstem tumors in children. Nerv Syst, 29 (8), 1313-9. doi: 10.1007/s00381-013-2101-0.
[10] Paugh B, Qu C, Jones C, Liu Z, Adamowicz-Brice M, Zhang J, et al. (2010) Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol, 28, 3061–3068.
[11] Paugh B, Broniscer A, Qu C, Miller C, Zhang J, Tatevossian R, et al. (2011) Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol, 29, 3999–4006.
[12] Zarghooni M, Bartels U, Lee E, Buczkowicz P, Morrison A, Huang A, et al. (2010) Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor α and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol, 28, 1337–1344.
[13] Barrow J, Adamowicz-Brice M, Cartmill M, Macarthur D, Lowe J, Robson K, et al. (2011) Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas. Neuro Oncol, 13, 212–222.
[14] Warren K, Killian K, Suuriniemi M, Wang Y, Quezado M, Meltzer P. (2011) Genomic aberrations in pediatric diffuse intrinsic pontine gliomas. Neuro Oncol, 14, 326–332.
[15] Grill J, Puget S, Andreiuolo F, Philippe C, Macconaill L, Kieran M. (2012) Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer, 58, 489–491.
[16] Li G, Mitra S, Monje M, Henrich K, Bangs C, Nitta R, et al. (2012) Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas. J Neurooncol, 108, 395–402.
[17] Wu G, Broniscer A, McEachron TA, et al. (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet, 44 (3), 251-3.
[18] Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol, 131, 803–20.
[19] Castel D, Philippe C, Calmon R, et al. (2015) Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol, 130 (6), 815–827. doi: 10.1007/s00401-015-1478-0.
[20] von Bueren AO, Karremann M, Gielen GH, et al. (2018) A suggestion to introduce the diagnosis of “diffuse midline glioma of the pons, H3 K27 wildtype (WHO grade IV)”. Acta Neuropathol, 36 (1), 171–173. doi: 10.1007/s00401-018-1863-6.
[21] Haas-Kogan D, Banerjee A, Poussaint T, Kocak M, Prados M, Geyer J, et al. (2018) Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol, 13 (3), 298-306.
[22] Grigsby P, Garcia D, Ghiselli R. (1989) Analysis of autopsy findings in patients treated with irradiation for thalamic and brain stem tumors. Am J Clin Oncol, 12, 255–258.
[23] Reyes-Botero G, Laigle-Donadey F, Mokhtari K, Martin-Duverneuil N, Delattre JY. (2014) Temozolomide after radiotherapy in recurrent “low grade” diffuse brainstem glioma in adults. J Neuroolcol, 120 (3), 581–6.10.1007/s11060-014-1589-9.
[24] Burzynski SR. (1976) Antineoplastons: Biochemical defense against cancer. Physiol Chem Phys, 8, 275-279.
[25] Burzynski SR. (1986) Synthetic antineoplastons and analogs: Drugs of the future, 11, 679-688. Reyes-Botero G, Laigle-Donadey F, Mokhtari K, Martin-Duverneuil N, Delattre JY. (2014) Temozolomide after radiotherapy in recurrent “low grade” diffuse brainstem glioma in adults. J Neurooncol. 120 (3), 581–6.10.1007/s11060-014-1589-9.
[26] Burzynski SR, Janicki T, Burzynski G. (2015) A phase II study of Antineoplastons A10 and AS2-1 in adult patients with primary brain tumors: Final report (Protocol BT-09), J Cancer Ther, 6, 1063-1074. doi.org/10.4236/jct.2015.612116.
[27] Wen, PK, Macdonald DR, Reardon DA, et al. (2010) Updated response criteria for high-grade gliomas: Response Assessment in Neuro-Oncology (RANO) working group. J Clin Oncol, 28 (11), 1963-1972.
[28] Burzynski SR, Patil S. (2014) The effect of Antineoplastons A10 and AS2-1 and metabolites of sodium phenylbutyrate on gene expression in glioblastoma multiforme. J Cancer Ther, 5, 929-945.
[29] Hawkins MG, Friedman MA. (1992) National Cancer Institute’s evaluation of unconventional cancer treatments. J Natl Cancer Inst, 84, 1699-1702.
[30] Burzynski SR, Janicki T, Burzynski G. (2015) Comprehensive genomic profiling of recurrent classic glioblastoma in a patient surviving eleven years following antineoplaston therapy. Cancer Clin Oncol, 4 (2), 41-52.
[31] Burzynski SR, Conde AB, Peters A, Saling B, Ellithorpe R, Daugherty JP, Nacht CH. (1999) A Retrospective Study of Antineoplastons A10 and AS2-1 in Primary Brain Tumors. Clin Drug Invest, 18, 1-10.
[32] Burzynski SR, Weaver RA, Bestak M, Lewy RI, Janicki TJ, Jurida, GF, Paszkowiak JK, Szymkowski BG, Khan MI. (2003) Phase II study of Antineoplastons A10 and AS2-1 (ANP) in children with recurrent and progressive multicentric glioma: A preliminary report. Neuro Oncol, 5, 358.
[33] Burzynski SR, Lewy RI, Weaver R, Janicki T, Jurida G, Khan M, Larisma CB, Paszkowiak J, Szymkowski B. (2004) Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme. Integ Cancer Ther, 3, 257-261. doi: 10.1177/1534735404267748.
[34] Burzynski SR, Weaver R, Lewy R, Janicki T, Jurida G, Szymkowski B, Khan M, Bestak M. (2004) Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma: A preliminary report. Drugs R&D, 5 (6), 315-326.
[35] Burzynski SR, Weaver R, Bestak M, Janicki T, Jurida G., Szymkowski B, Khan M, Dolgopolov V. (2004) Phase II studies of antineoplastons A10 and AS2-1 (ANP) in children with atypical teratoid/rhabdoid tumors (AT/RT) of the central nervous system: A preliminary report. Neuro Oncol, 6, 427.
[36] Burzynski SR, Weaver R, Bestak M, Janicki T, Szymkowski B, Jurida G, Khan M, Dolgopolov, V. (2004) Treatment of primitive neuroectodermal tumors (PNET) with antineoplastons A10 and AS2-1 (ANP): Preliminary results of phase II studies. Neuro Oncol 6, 428.
[37] Burzynski SR, Weaver RA, Janicki, T, Szymkowski B, Jurida G, Khan M, Dolgopolov V. (2005) Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with Antineoplastons A10 and AS2-1. Integ Cancer Ther, 4 (2); 168-177. doi: 10.1177/1534735404267748.
[38] Burzynski SR. (2006) Targeted Therapy for Brain Tumors. In: Yang AV, editor. Brain Cancer Therapy and Surgical Interventions. Nova Science Publishers, Inc, New York.
[39] Burzynski SR, Janicki, TJ, Weaver RA, Burzynski B. (2006) Targeted therapy with Antineoplastons A10 and AS2-1 of high grade, recurrent, and progressive brainstem glioma. Integ Cancer Ther, 5 (1), 40-47. doi: 10.1177/1534735405285380.
[40] Burzynski SR. (2006) Treatments for astrocytic tumors in children: Current and emerging strategies. Ped Drugs, 8, 167-168. doi.org/10.2165/00148581-200608030-00003.
[41] Burzynski SR. (2007) Recent clinical trials in diffuse intrinsic brainstem glioma. Cancer Ther, 5, 379- 390.
[42] Burzynski S, Janicki T, Burzynski G, Marszalek A. (2014) Long-term survival (>13 years) in a child with recurrent diffuse pontine gliosarcoma: A case report. J Ped Hematol Oncol, 36: 433-439. doi: 10.1097/MPH.0000000000000020
[43] Burzynski SR, Janicki TJ, Burzynski GS, Marszalek A. (2014) A phase II study of antineoplastons A10 and AS2-1 in children with high-grade glioma: Final report (Protocol BT-06) and review of recent trials. J Cancer Ther, 5, 565-577. doi.org/10.4236/jct.2014.56065.
[44] Burzynski SR, Janicki TJ, Burzynski GS. (2014) A phase II study of antineoplastons A10 and AS2-1 in adult patients with recurrent glioblastoma multiforme: Final report (Protocol BT-21). J Cancer Ther, 5, 946-956. doi.org/10.4236/jct.2014.510100.
[45] Burzynski SR, Burzynski GS, Janicki TJ. (2014) Recurrent glioblastoma multiforme: A strategy for long-term survival. J Cancer Ther, 5, 957-976. doi.org/10.4236/jct.2014.510101.
[46] Burzynski SR, Janicki TJ, Burzynski, GS, Marszalek A, Brookman S. (2014) A phase II study of antineoplastons A10 and AS2-1 in children with recurrent, refractory or progressive primary brain tumors: Final report (Protocol BT-22). J Cancer Ther, 5, 977-988. doi.org/10.4236/jct.2014.510102.
[47] Burzynski SR, Janicki TJ, Burzynski GS, Brookman S. (2014) Preliminary findings on the use of targeted therapy with pazopanib and other agents in combination with sodium phenylbutyrate in the treatment of glioblastoma multiforme. J Cancer Ther, 5, 1423-1437.
[48] Burzynski GS, Janicki TJ, Marszalek A. (2014) Long-term survival (>20 years) of a child with brainstem glioma treated with antineoplastons A10 and AS2-1: A case report. Neuro Oncol, 11, 16.
[49] Burzynski SR, Janicki TJ, Burzynski GS, Marszalek. (2014) The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma. Childs Nerv Syst, 30; 2051-2061. doi.org/ 10.1007/s00381- 014-2401-z.
[50] Burzynski SR, Burzynski G, Janicki J, Marszalek A. (2015) Complete response and Long-term survival (>20 years) of a child with tectal glioma: A case report. Pediatr Neurosurg, 50, 99-103. doi: 10.1159/000369907.
[51] Burzynski SR, Janicki TJ, Burzynski G. (2015) A phase II study of Antineoplastons A10 and AS2-1 injections in adult patients with recurrent anaplastic astrocytoma: Final report (Protocol BT-15). Cancer Clin Oncol, 442, 13-23.
[52] Burzynski SR, Janicki TJ, Burzynski GS, Marszalek A. (2015) A Phase II Study of Antineoplastons A10 and AS2-1 in adult patients with newly-diagnosed anaplastic astrocytoma: Final report (Protocol BT-08). Cancer Clin Oncol, 4, 28-38.
[53] Burzynski SR, Burzynski GS, Marszalek A, Janicki J, Martinez-Canca J. (2015) Long-term survival (over 20 years), complete response and normal childhood development in medulloblastoma treated with Antineoplastons A10 and AS2-1. J Neurol Stroke, 2 (3), 00054.
[54] Burzynski SR, Burzynski GS, Marszalek A, Janicki TJ, Martinez-Canca JF. (2015) Long-term survival over 21 years and pathologically confirmed complete response in pediatric anaplastic astrocytoma: A case report. J Neurol Stroke, 2 (6), 00072.
[55] Burzynski SR, Burzynski GS, Brookman S. (2015) A case of sustained objective response of recurrent/progressive diffuse intrinsic pontine glioma with phenylbutyrate and targeted agents. J Cancer Ther, 6, 40-44. doi: 10.4236/jct.2015.61006.
[56] Burzynski SR, Janicki, T, Burzynski G, Marszalek A. (2015) A phase II study of antineoplastons A10 and AS2-1 in patients with brainstem gliomas: The report on non-diffuse intrinsic pontine glioma (Protocol BT-11). J Cancer Ther, 6, 334-344. doi: 10.4236/jct.2017.82015.
[57] Burzynski SR, Janicki TJ, Burzynski GS. (2016) Primary CNS tumors and leptomeningeal, disseminated and/or multicentric disease in children treated in Phase II studies with Antineoplastons A10 and AS2-1. Cancer Clin Oncol, 5 (2), 38-48.
[58] Burzynski SR, Janicki TJ, Burzynski GS. (2016) A phase II study of antineoplastons A10 and AS2-1 in children with low-grade astrocytomas: Final report (Protocol BT-13). J Cancer Ther, 7 (12): 837-850.
[59] Burzynski SR, Janicki TJ, Burzynski GS. (2017) Antineoplastons A10 and AS2-1 in the treatment of children with optic pathway glioma: Final report for protocol BT-23. Cancer Clin Oncol, 6 (1), 25-35.
[60] Burzynski SR, Janicki TJ, Burzynski GS, Marszalek A. (2017) A phase II study of Antineoplastons A10 and AS2-1 in children with brain tumors: Final report (Protocol BT-10). J Cancer Ther, 8, 173-187.
[61] Burzynski SR, Janicki T, Beenken, S. (2019) Treatment of recurrent glioblastoma multiforme (rGBM) with Antineoplaston AS2-1 in combination with targeted therapy. Cancer Clin Oncol, 8, 1-15.
[62] Burzynski, SR, Burzynski, GS, Janicki, T, Beenken S. (2021) Long-term survival (23 years) in a 26-year-old male after Antineoplaston therapy for a progressive, diffuse intrinsic pontine glioma: A case report. Int J Brain Disord Treat, 6, 038-044. doi.org/10.23937/2469-5866/.
[63] Burzynski, SR, Janicki T, Burzynski GS, Beenken S. (2021) Resolution of clinical signs, a complete response, and long-term survival (>23 Years) in a 3 and ½ month female with a newly diagnosed diffuse intrinsic pontine glioma treated with antineoplastons. Biomed Res Clin Prac, 6: doi: 10.15761/BRCP.1000220.
[64] Burzynski, SR, Janicki T, Burzynski GS, Beenken S. (2021) Diffuse intrinsic pontine glioma in an 11-year-old female treated with antineoplastons: Complete response and > 25-year survival. In Press.
Cite This Article
  • APA Style

    Stanislaw Rajmund Burzynski, Gregory Burzynski, Tomasz Janicki, Samuel Beenken. (2022). A 25-year-female with Diffuse Intrinsic Pontine Glioma Surviving for More than Nine Years Following Treatment with Antineoplastons. International Journal of Clinical Oncology and Cancer Research, 7(1), 1-7. https://doi.org/10.11648/j.ijcocr.20220701.11

    Copy | Download

    ACS Style

    Stanislaw Rajmund Burzynski; Gregory Burzynski; Tomasz Janicki; Samuel Beenken. A 25-year-female with Diffuse Intrinsic Pontine Glioma Surviving for More than Nine Years Following Treatment with Antineoplastons. Int. J. Clin. Oncol. Cancer Res. 2022, 7(1), 1-7. doi: 10.11648/j.ijcocr.20220701.11

    Copy | Download

    AMA Style

    Stanislaw Rajmund Burzynski, Gregory Burzynski, Tomasz Janicki, Samuel Beenken. A 25-year-female with Diffuse Intrinsic Pontine Glioma Surviving for More than Nine Years Following Treatment with Antineoplastons. Int J Clin Oncol Cancer Res. 2022;7(1):1-7. doi: 10.11648/j.ijcocr.20220701.11

    Copy | Download

  • @article{10.11648/j.ijcocr.20220701.11,
      author = {Stanislaw Rajmund Burzynski and Gregory Burzynski and Tomasz Janicki and Samuel Beenken},
      title = {A 25-year-female with Diffuse Intrinsic Pontine Glioma Surviving for More than Nine Years Following Treatment with Antineoplastons},
      journal = {International Journal of Clinical Oncology and Cancer Research},
      volume = {7},
      number = {1},
      pages = {1-7},
      doi = {10.11648/j.ijcocr.20220701.11},
      url = {https://doi.org/10.11648/j.ijcocr.20220701.11},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcocr.20220701.11},
      abstract = {Rationale: Diffuse intrinsic pontine glioma (DIPG) is a lethal brain tumor and leading cause of brain tumor–related death in children. Over the past few decades, clinical trials have shown no improvement in outcome. Most DIPGs occur in the pediatric population. Adult brainstem gliomas are rare, constitute less than 2% of adult gliomas, and show a slight male predominance. The case of this 25-year-old female is presented to detail and discuss the use of Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal) in the treatment of DIPG that persisted despite radiation therapy (RT) and temozolomide. Objectives: The patient described was treated at the Burzynski Clinic (BC), as a special exception, according to the phase II protocol, BT-09, which utilized Antineoplastons A10 and AS2-1 (ANP therapy) in the treatment of brain tumors. The delivery of ANP therapy was via a subclavian catheter and infusion pump. Tumor response to therapy was measured by sequential magnetic resonance imaging (MRI) of the brain. Overall Survival (OS) and Adverse Events (AES) were also documented. Findings: At her presentation to the BC, the patient complained of diplopia, left-sided weakness, and difficulty walking. On physical exam, she was alert and orientated. Her cranial nerves were intact. There was weakness of the left-sided extremities. Deep tendon reflexes were equal bilaterally with down-going toes bilaterally. Reports of the original brain MRIs in Argentina suggested a DIPG with extension to the medulla and cerebellum. In addition, tumor biopsy confirmed a grade 3 astrocytoma. Following radiation therapy (RT) and temozolomide in Argentina, the patient was treated at BC for persistent disease with ANP therapy. Sequential MRI imaging of the residual tumor, which was non-enhancing, showed no change in size during therapy. However, the patient did achieve resolution of her neurologic signs and symptoms and has survived more than nine years since first being seen at BC. Correspondence with the patient on September 9, 2021 indicated she was feeling fine, had a healthy child, and was enjoying life. Conclusions: We have presented here the case of an adult female with a DIPG who had resolution of signs and symptoms and survived more than nine years after ANP therapy. For patients with DIPG (or other high-grade astrocytoma), who do not qualify for/refuse RT or show persistent or progressive disease following RT and/or chemotherapy, ANP therapy is an effective therapeutic option. In collaboration with the FDA confirmatory Phase II and Phase III studies have been developed.},
     year = {2022}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - A 25-year-female with Diffuse Intrinsic Pontine Glioma Surviving for More than Nine Years Following Treatment with Antineoplastons
    AU  - Stanislaw Rajmund Burzynski
    AU  - Gregory Burzynski
    AU  - Tomasz Janicki
    AU  - Samuel Beenken
    Y1  - 2022/02/05
    PY  - 2022
    N1  - https://doi.org/10.11648/j.ijcocr.20220701.11
    DO  - 10.11648/j.ijcocr.20220701.11
    T2  - International Journal of Clinical Oncology and Cancer Research
    JF  - International Journal of Clinical Oncology and Cancer Research
    JO  - International Journal of Clinical Oncology and Cancer Research
    SP  - 1
    EP  - 7
    PB  - Science Publishing Group
    SN  - 2578-9511
    UR  - https://doi.org/10.11648/j.ijcocr.20220701.11
    AB  - Rationale: Diffuse intrinsic pontine glioma (DIPG) is a lethal brain tumor and leading cause of brain tumor–related death in children. Over the past few decades, clinical trials have shown no improvement in outcome. Most DIPGs occur in the pediatric population. Adult brainstem gliomas are rare, constitute less than 2% of adult gliomas, and show a slight male predominance. The case of this 25-year-old female is presented to detail and discuss the use of Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal) in the treatment of DIPG that persisted despite radiation therapy (RT) and temozolomide. Objectives: The patient described was treated at the Burzynski Clinic (BC), as a special exception, according to the phase II protocol, BT-09, which utilized Antineoplastons A10 and AS2-1 (ANP therapy) in the treatment of brain tumors. The delivery of ANP therapy was via a subclavian catheter and infusion pump. Tumor response to therapy was measured by sequential magnetic resonance imaging (MRI) of the brain. Overall Survival (OS) and Adverse Events (AES) were also documented. Findings: At her presentation to the BC, the patient complained of diplopia, left-sided weakness, and difficulty walking. On physical exam, she was alert and orientated. Her cranial nerves were intact. There was weakness of the left-sided extremities. Deep tendon reflexes were equal bilaterally with down-going toes bilaterally. Reports of the original brain MRIs in Argentina suggested a DIPG with extension to the medulla and cerebellum. In addition, tumor biopsy confirmed a grade 3 astrocytoma. Following radiation therapy (RT) and temozolomide in Argentina, the patient was treated at BC for persistent disease with ANP therapy. Sequential MRI imaging of the residual tumor, which was non-enhancing, showed no change in size during therapy. However, the patient did achieve resolution of her neurologic signs and symptoms and has survived more than nine years since first being seen at BC. Correspondence with the patient on September 9, 2021 indicated she was feeling fine, had a healthy child, and was enjoying life. Conclusions: We have presented here the case of an adult female with a DIPG who had resolution of signs and symptoms and survived more than nine years after ANP therapy. For patients with DIPG (or other high-grade astrocytoma), who do not qualify for/refuse RT or show persistent or progressive disease following RT and/or chemotherapy, ANP therapy is an effective therapeutic option. In collaboration with the FDA confirmatory Phase II and Phase III studies have been developed.
    VL  - 7
    IS  - 1
    ER  - 

    Copy | Download

Author Information
  • Medical Division, Burzynski Clinic, Houston, USA

  • Medical Division, Burzynski Clinic, Houston, USA

  • Medical Division, Burzynski Clinic, Houston, USA

  • Oncology Writings, Calera, USA

  • Sections